Trials / Completed
CompletedNCT05294627
Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss Population
Validation of the Prostate Cancer Biomarker Stockholm3 for Improved Disease Detection and Classification in the Swiss Population
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 380 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. \>2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Stockholm3 | Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2022-11-01
- Completion
- 2023-10-01
- First posted
- 2022-03-24
- Last updated
- 2023-12-12
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05294627. Inclusion in this directory is not an endorsement.